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ABSTRACT AICAR is a natural compound, an analogue and precursor of adenosine. As activator of AMP-activated 
protein kinase (AMPK), AICAR has a broad therapeutic potential, since it normalizes the carbohydrate and lipid 
metabolism and inhibits the proliferation of tumor cells. The synthesis of AICAR in Bacillus subtilis cells is con-
trolled by the enzymes of purine biosynthesis; their genes constituting purine operon (pur-operon).  Reconstruc-
tion of purine metabolism in B. subtilis was performed to achieve  overproduction of AICAR. For this purpose, 
the gene purH, which encodes formyltransferase/IMP-cyclohydrolase, an enzyme that controls the conversion 
of AICAR to IMP, was removed from the B. subtilis genome, ensuring the accumulation of AICAR. An insertion 
inactivating the gene purR that encodes the negative transcriptional regulator of the purine biosynthesis operon 
was introduced into the B.subtilis chromosome in order to boost the production of AICAR; the transcription 
attenuator located in the leader sequence of pur-operon was deleted. Furthermore, the expression integrative 
vector carrying a strong promoter of the rpsF gene encoding the ribosomal protein S6 was designed. The heter-
ologous Escherichia coli gene purF encoding the first enzyme of the biosynthesis of purines with  impaired al-
losteric regulation, as well as the modified E.coli gene prs responsible for the synthesis of the precursor of pu-
rines — phosphoribosyl pyrophosphate (PRPP) — was cloned into this vector under the control of the rpsF gene 
promoter. The modified purF and prs genes were inserted into the chromosome of the B. subtilis strain. B. subtilis 
strain obtained by these genetic manipulations accumulates 11–13 g/L of AICAR in the culture fluid. 
KEYWORDS anticancer agent AICAR; purine metabolism; genome reconstruction; Bacillus subtilis strain - pro-
ducer of AICAR
ABBREVIATIONS AICAR – 5-aminoimidazole-4-carboxamide ribofuranoside; AICAR-P – nucleotide AICAR 
phosphate; IMP – inosine monophosphate; AMP – adenosine monophosphate; АМPK – 5’-adenosine monophos-
phate-activated protein kinase; PRPP – phosphoribosyl pyrophosphate; GAR – 5’- phosphoribosyl glycineamide 
ribonucleotide; GMP – guanosine monophosphate; PCR – polymerase chain reaction; CF – culture fluid
INTRODUCTION
Despite the fact that the structural organization of the 
genes encoding the enzymes of purine nucleotide bi-
osynthesis is quite versatile, the biochemistry of the 
process is conservative for different organisms: the 
formation of the purine cycle occurs on the basis of a 
riboso-5-phosphate (all intermediates are nucleotides) 
using a monocarbon component (formiate and/or N10-
formyltetrahydrofolate) [1]. There is demand for mono-
carbon compounds at two stages of purine biosynthesis; 
therefore, the precursors – phosphoribosylglycinea-
mide ribonucleoside (GAR) and 5-aminoimidazole-
4-carboxamide ribonucleoside (AICAR-P) can be ac-
cumulated if there is a deficiency in these compounds. 
Among them, AICAR-P occupies a specific place, since 
its formulation and subsequent cyclization crown the 
formation of the purine heterocycle that yields inosine 
monophosphate (IMP) (Fig. 1). The process of conver-
sion of AICAR-P into IMP in prokaryotic cells is con-
trolled by the gene purH, which encodes two domains 
with the activities of AICAR-P-formyltransferase and 
IMP cyclohydrolase [2, 3].  Further modifications of 
IMP yield AMP and GMP.
Despite the fact that the structure of purine hetero-
cycle is incomplete, AICAR-P is a natural analogue of 
AMP, substituting it in certain enzymatic in vitro reac-
tions. The possibility that AMP could be substituted in 
the reactions of activation of AMP-activated proteinki-
nase (AMPK) in mammals has been given a significant 
degree of attention over the past decade. AMPK is the 
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global regulator of the metabolic processes ensuring 
the energy status of the eukaryotic organism [4, 5]. For 
in vivo activation of AMPK, it is convenient to use a 
AICAR nucleoside, which can be rapidly phosphoryl-
ated in cells, yielding AICAR-P, an analogue of AMP. 
The emergence of AICAR-P imitates the accumulation 
of AMP and provokes the rearrangement of energy 
processes directed towards the overcoming of imagi-
nary energetic stress. Due to their ability to activate 
AMPK, AICAR-based drugs have a broad therapeu-
tic potential, since they normalize both the carbon [6] 
and lipid [7] metabolism. AICAR suppresses tumor 
cell growth by imitating the state of energetic stress 
[8]. The efficacy of AICAR in the prevention of type 2 
diabetes mellitus has been demonstrated [9]. AICAR 
induces apoptosis; it is efficient upon chronic [10] and 
acute leukoses [11].
The present work was aimed at obtaining the strain 
producer of AICAR by directed reconstruction of pu-
rine metabolism in B. subtilis cells. The choice of B. sub-
tilis was conditioned on the fact that genetic control 
and regulation of purine metabolism in these bacte-
ria have been subjected to an appropriately thorough 
study. Furthermore, Bacillus strains have been in use 
for a significant length of time as producers of purine 
nucleosides and nucleotides, such as inosine and inosin-
ic, as well as guanosinic, acids [12, 13].
Purine operon B. subtilis, purEKBCSQLFMNHD 
(hereafter referred to as pur-operon), encodes the en-
zymes of the synthesis of IMP, the most significant in-
termediate compound upon purine nucleotide biosyn-
thesis (Fig. 1). 
The group consisting of 12 linked genes that form 
the pur-operon is localized at the 55° region on the 
chromosome of B. subtilis (Fig. 2) [14]. Expression of the 
pur-operon of B. subtilis undergoes a double- negative 
regulation, by the protein-repressor PurR [15] and the 
transcription attenuator located in the leader sequence 
of pur-operon  [16].  It was shown that PRPP acts as 
a low-molecular-weight effector of the PurR protein 
[15], whereas guanine serves as a modulator enhancing 
transcription termination prior to the first structural 
gene of the operon [17]. Later, it was revealed that a 
5’-non-translatable sequence of mRNA has a sensory 
function with respect to the metabolite – guanine ef-
fector, and that it acts as the so-called riboswitch [18, 
19], providing early termination of operon transcription 
[20, 21]. 
Thus, maximum pur-operon gene expression had 
to be made possible at the first stage of obtainment of 
the strain producer of AICAR by eliminating the nega-
tive regulation of the pur-operon under the action of 
the protein repressor PurR and the transcription at-
tenuator in the leader sequence of the operon. The gene 
purH encoding formyltransferase/IMP-cyclohydro-
lase, which participates in the synthesis of AICAR, was 
then deleted from the genome of the resulting strain. 
Inactivation of this enzyme is intended to ensure the 
intracellular accumulation of AICAR (Fig. 1). At the 
next stage, the pool of major precursors of de novo pu-
rine synthesis — PRPP — was to be increased. PRPP 
is synthesized from riboso-5-phosphate under the con-
trol of PRPP synthase encoded by the prs gene. This 
enzyme is susceptible to allosteric regulation with the 
participation of purine nucleotides. The structural and 
functional organization of PRPP synthase was stud-
ied more thoroughly in E. coli bacteria, in which a mu-
tant variant of this enzyme, with eliminated allosteric 
regulation, was obtained [22]. Taking these data into 
account, site-directed mutagenesis of the prs gene of 
E. coli aimed at obtaining a mutant enzyme that would 
not be susceptible to retroinhibition by purine nucleo-
tides was preformed with the purpose of its subsequent 
transfer into B. subtilis cells. .
An additional impediment in the effort to boost AI-
CAR production is the allostreric regulation of the first 
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Fig. 1. De novo purine nucleotide biosynthesis in 
B. subtilis. Representative enzymatic steps of de novo 
purine biosynthesis are shown by the corresponding 
gene designations. Abbreviations: PRPP - 5’-phos-
phoribosyl-1-pyrophosphate, PRA-5’-phosphori-
bosylamine, GAR - 5’-phosphoribosylglycineamide, 
FGAR - 5’-phosphoribosyl-N-formylglycineamide, 
FGAM - 5’- phosphoribosyl-N-formylglycinamidine, AIR - 
5’-phosphoribosyl-5-aminoimidazole, CAIR - 5’-phosphori-
bosyl-4-carboxy-5-aminoimidazole, SAICAR - 5’-phos-
phoribosyl-4 (N- succinocarboxamide)-5-aminoimidazole, 
AICAR-P - 5’- phosphoribosyl - 4-carboxamide-5- aminoim-
idazole, FAICAR - 5-formamidoimidazole-4-carboxamide 
ribotide, IMP - inosine 5’-monophosphate, AICAR - 5-ami-
noimidazole-4-carboxamide 1-β-D-ribofuranoside.RESEARCH ARTICLES
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enzyme of purine biosynthesis — glutamine–PRPP 
aminotransferase encoded by the purF gene [23]. It is 
well known that glutamine–PRPP aminotransferase 
from E. coli, as opposed to the enzyme from B. subti-
lis, is not susceptible to inactivation in the steady-state 
stage of bacterial growth [24]. Moreover, the mutant 
variant of this enzyme, which is resistant to inhibition 
by purine nucleotides, has been described for E. coli 
[25]. Therefore, in our case the decision was made to 
use the glutamine–PRPP aminotransferase from E. coli 
modified by site-directed mutagenesis with the aim of 
subsequently transferring it into B. subtilis cells. An 
integrative expression vector based on plasmid pDG268 
was constructed comprising a strong promoter of the 
rpsF gene, which encodes the ribosomal protein S6, in 
order to ensure the optimal expression of the modified 
prs and purF genes of E. coli in B. subtilis cells. The fi-
nal stage of the process comprised the integration of 
the resulting vector, containing clones of the prs and 
purF genes under the control of the  rpsF gene pro-
moter, into the chromosome of the AICAR-producing 
strain  B. subtilis.
EXPERIMENTAL
Bacterial strains and plasmids
The bacterial strains and plasmids used in this study 
are listed in Table 1. The B. subtilis strain AM732 was 
obtained via the transformation of the Mu8u5u6 strain 
of chromosomal DNA isolated from the B. subtilis strain 
168 with the selection of Pur+ transformants. Strain 
AM743 was obtained by the transformation of strain 
АМ732 of chromosomal DNA isolated from B. subtilis 
strain LCC28 with the selection of transformants NeoR 
in a neomycine-containing medium.
Media and culturing conditions
A LB medium [31], or the standard-minimal Spizizen’s 
medium, with the required additives [26] was used as 
the nutrient medium to culture bacteria. Aminoacids 
were added in an amount of 50 µg/mL. Glucose (0.4%) 
was used as a source of carbon. The following antibi-
otics were added into the medium when necessary: 
ampicillin (Amp) – 100 µg/mL; chloramphenicol (Cm) 
– 10 µg/mL; erythromycin (Em) – 1 mg/mL; and neo-
mycin (Neo) – 5 µg/mL. Methionine and leucine were 
added at a concentration of 50 µg/mL. Hypoxantine, 
adenine, or guanine (20 µg/mL) was used as a purine 
source for purine auxotrophs. The DNA of B. subtilis 
was isolated according to the Saito–Miura procedure 
[32]; the transformation experiments were carried out in 
accordance with Anagnostopoulos and Spizizen’s work 
[26].
Manipulations with plasmid DNA
The isolation of plasmid DNA, cloning, transformation 
into E. coli cells, and analysis of recombinant plasmids 
were performed using the standard methods [31].
Enzyme preparations
Restriction endonucleases, T4-DNA-ligase, and ther-
mostable Taq DNA polymerase were purchased from 
Fermentas International Inc.
Polymerase chain reaction
The PCR was performed on a MyCycler thermal cycler 
(Bio-Rad Laboratories). The temperature mode was se-
lected with due consideration of the length of the am-
plified fragment, as well as the length and composition 
of the primers used. The isolation and purification of 
the PCR products was carried out using a Silica Bead 
DNA Gel Extraction Kit (Fermentas International Inc.).
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Fig. 2. Scheme of structural organization of the B. subtilis pur-operon and its regulation. Top: relative location of the 12 
linked structural genes that constitute the pur-operon and unlinked purR gene, encoding a repressor of pur-operon. 
Bottom: the leader region of pur-operon, including binding sites for the repressor protein PurR, binding site for RNA 
polymerase (-35 ; - 10), transcription start (+1), the terminator of transcription (hairpin structure) and the ribosome 
binding site (SD); the dotted line denotes deletion of the leader region of pur-operon (∆T-purE).82 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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Site-directed mutagenesis
Site-directed mutagenesis was performed using spe-
cific oligonucleotide primers. The composition and 
characteristics of the primers are listed in Table 2. The 
presence of corresponding mutations was verified by 
sequencing according to Sanger [33].
Fermentation conditions
The ability of the strains obtained during the study to 
accumulate AICAR in culture liquid (CL) was assessed. 
The strain inoculum was cultivated at 37oC for 18 h on 
a LB broth. Then, 0.5 mL of the culture was added to 
each 20 x 200 mm vial with 4.5 mL of the fermenta-
tion medium and cultured at 37oC for 72 h on a rotary 
shaker. The fermentation medium had the following 
composition (%): soy flour – 3; nutrient yeast – 1; corn 
extract – 5; (NH4)2HPO4 – 0.6; carbamide – 0.4; and 
sugar – 15, pH 7.0.
Determination of AICAR concentration in the culture 
liquid
The CL obtained during fermentation was centrifuged 
to remove the cells; the AICAR concentration was then 
determined in the supernatant on Sorbfil plates (OOO 
Lenchrom, Saint Petersburg, Russia) by quantitative 
thin-layer chromatography. The composition of the 
eluting system designed was as follows: chloroform–
methanol–water–25% aqueous solution of ammonia 
at a volume ratio of 5 : 3 : 1.  Quantitative HPLC on a 
chromatograph (ALLIANCE, Separations Module Wa-
ters 2695, Photodiode Array detector Waters 2996) was 
employed as an alternative method.
RESULTS AND DISCUSSION
Enhancement of the expression of the B. subtilis pur-
operon
In work [21] devoted to the study of  B. subtilis pur-
operon expression, it was demonstrated that an al-
most 20-fold enhancement of the expression of the 
lacZ reporter gene integrated into the purH gene, as 
compared with the expression in the wild-type strain 
when the purR gene that encodes the repressor pro-
tein of the operon is damaged, is achieved. After dele-
tion of 94 n.p. of the wild-type strain, which captures 
the Rho-independent transcription attenuator (ΔT-
Table 1. Bacteria and plasmids used in the present study
Strain or plasmid Description or genotype Source or reference
Bacillus subtilis
168 trpC [26]
Mu8u5u6 leu met purF [27]
LCC28 purR::neo [28]
AM747 trpC purH::(pMutin2purH’-lacZ) ΔT-purE [21]
АМ732 leu met This study
AM743 leu met purR::neo - “ -
АМ764 leu met purR::neo ΔT-purE - “ -
АМ778 leu met purR::neo ΔT-purE ΔpurH - “ -
АМ793 leu met ΔpurH - “ -
АМ811 leu met purR::neo ΔT-purE ΔpurH amyE::[PrpsF-prsE] - “ -
АМ813 leu met purR::neo ΔT-purE ΔpurH amyE::[PrpsF-purFE] - “ -
АМ815 leu met purR::neo ΔT-purE ΔT ΔpurH amyE::[PrpsF-prsE-purFE] - “ -
E.coli
TG1 thi supE hsdΔ5 Δ(lac-proAB)/F’tra Δ36 proAB(+) lacI(q) lacZ ΔM15 VKPM
MG1655 prototroph [29]
Plasmids:
pDG268 Apr (E.coli) Cmr (B.subtilis) [18]
pNZT1 Emr [30]
pLE1 as pDG268, but contains a promoter of rpsFE gene This study
pLE2 as pLE1, but contains a prsE gene - “ -
pLE3 as pLE1, but contains a purFE gene  - “ -
pLE4 as pLE1, but contains a prsE и purFE genes - “ -
Apr – ampicillin resistance, Emr erythromycin resistance, Cmr – chloramphenicol resistance.
VKPM Russian National Collection of Industrial MicroorganismsRESEARCH ARTICLES
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purE) located in the leader region of the pur-operon 
(Fig. 2), the expression of the lacZ reporter gene in-
creased approximately by a factor of 10. However, 
when combining both mutations, a pronounced syn-
ergic effect was observed; lacZ gene expression in-
creased by a factor of more than 200. Taking these 
data into account, the experiments on the inactivation 
of the purR gene and deletion of the transcription at-
tenuator (ΔT-purE) were performed at the first stage 
of construction of the AICAR-producing strain.
The AM732-Pur+ strain, a derivative of the earlier 
characterized Mu8u5u6 strain [21] (Table 1), was used 
as starting material. In order to transfer the purR::neo 
insertion, which completely inactivates the synthesis 
of the PurR repressor protein, into the genome of the 
АМ732 strain, this strain was transformed by chro-
mosomal DNA isolated from the LCC28 (purR::neo) 
strain, with the selection of recombinants that were   
resistant to neomycin (NeoR). As a result, the АМ743 
purR::neo strain was selected for use in the subsequent 
work (Table 1). The deletion ΔT-purE in the genome 
of the АМ743 purR::neo strain was obtained through   
the following scheme. First, the long-stretched deletion 
ΔL-E was obtained, completely overlapping the leader 
region of the pur-operon and partially overlapping the 
first structural gene purE, which resulted in the emer-
gence of auxotrophicity with respect to purines. How 
to achieve this deletion was thoroughly described in 
[21]. The deletion of the transcription attenuator ΔT-
purE was transferred into the AM743 purR::neo ΔL-E 
strain by transforming DNA that was isolated from 
the AM747 strain (Table 1); Pur+ transformants were 
selected on the purine-free Spizizen’s minimal me-
dium. As a result, the АМ764 strain was obtained. It 
contained the purR::neo insertion and deletion of the 
transcription attenuator ΔT-purE in the genome.
Obtaining the deletion of the purH gene in the B. sub-
tilis chromosome 
As follows from the schematic representation of purine 
biosynthesis (Fig. 1), for intracellular accumulation of 
AICAR, it is necessary to inactivate formyltransferase/
IMP-cyclohydrolase encoded by the purH gene. The 
PurH gene deletion in the B. subtilis chromosome was 
achieved using the method described in [30] based on 
using a specially constructed pNZT1plasmid, a deriva-
tive of the integrative vector pKS1 [34]. The pNZT1 
plasmid contains the erythromycine (EmR) resistance 
marker and a polylinker with multiple restriction sites 
for cloning the target fragments of chromosomal DNA.   
Of paramount importance is the fact that its replication 
is temperature-sensitive: at 30оС, the plasmid exists in 
Table 2. Primers used in this study
Name Gene Sequence*
Coordinates **
 5’ 3’
N1 purNB cccccgcgggcggaacgattccacat (SacII) +135 +154
N2 purNB cgcctgcagttcttttacgaaaggaacga (PstI) +652  +630
D1 purDB cgcctgcagcttcaaacattaaggggatgaaaa(PstI) -28 -5
D2 purDB cgcggtacctttttcctgcacatatgcc (KpnI) +410 +389
F1  purFE cgcatcgataggaggtgcaaacagatgtgcggtattgtcggtatc (ClaI)      +1 +22
F2 purFE cgcgctcagcgaaggcatcatcct (EspI) +1530  +1511 
F3 purFE gggcttcgttCaaaaccgctat   +968 +991
F4 purFE atagcggttttGaacgaagccc   +991 +968
F5 purFE ggtattgatatgTGgagcgccacgg  +1216 +1242
F6 purFE ccgtggcgctcCAcatatcaatacc  +1242 +1216
P1 prsE cgcggatccaaggaggttcttctcAtgcctgatatga (BamHI)  -21 +3
P2 prsE cccatcgatgccgggttcgattagtgttcga (ClaI) +949 +928
P3 prsE ctgacagtggCtctgcacgctg    +366 +377
P4 prsE agcgtgcagaGccactgtcagc    +377 +366
R1 rpsFB cgcgaattcttgcgggcggcggtat (EcoRI) -223 -205
R2 rpsFB cgcggatccataatgggcaaggagcaat (BamHI)  -31 -51
*The sequence of primers is given in the orientation 5’-3 ‘. Uppercase bold letters indicate the nucleotide substitutions 
introduced in primers for site-directed mutagenesis. Recognition sites are underlined. Restriction enzymes are shown in 
parentheses.
**The coordinates of the 5’-and 3’-ends of the primers are relative to the start of translation of the corresponding genes. 
B. subtilis genes are marked with the symbol (B); and E. coli - with the symbol (E).84 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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an autonomous state. However, at 37оС the replication 
is blocked. As a result, if the plasmid has a chromo -
some fragment cloned into its structure, it is capable 
of integration into the chromosome by homologous re-
combination (Fig. 3). Since plasmid integration into the 
chromosome results from the single recombination act 
in the homology region between the cloned fragment 
and the chromosome, the integration site of the plasmid 
into the chromosome turns out to be flanked by homol-
ogous duplicated sequences. Culturing of these bacte-
ria at 30оС (permissive, for pNZT1 plasmid replication) 
may result in its removal from the chromosome with 
capture of a copy of the flanked chromosome sequenc-
es, which allows for the replacement of the wild allele 
of any chromosome gene by the mutant gene cloned in 
the pNZT1 plasmid (Fig. 3).
This feature of the pNZT1 plasmid was used for the 
deletion of the purH gene. With this aim in mind, the 
PCR amplification of the chromosome fragments that 
flanked the purH gene was performed. A distal region 
(517 np) of the purN gene adjacent to the 5’-termi-
nus of the purH gene was amplified using N1 and N2 
primers, followed by cloning into pNZT1 plasmid at re-
strictases SacII and PstI digestion sites. The proximal 
region (442 np) of the purD gene adjacent to the 3’-ter-
minus of the purH gene was amplified at the next stage 
using D1 and D2 primers (Table 2), followed by cloning 
at restrictases PstI and KpnI digestion sites into the 
pNZT1 plasmid that was obtained at the previous stage 
and contained the insertion of the purN gene fragment. 
The E. coli strain TG1 was transformed by this plas-
mid. EmR transformants were sampled from a medium 
with erythromycin (300 µg/mL) at 30оС. The presence 
of the pNZT1 plasmid with cloned purN and purD gene 
fragments was tested in the resulting clones using PCR. 
The АМ764 purR::neo ΔT-purE strain was transformed 
by pNZT1-purN-purD plasmids isolated from the in-
spected clones. The selection of the EmR transformants 
was carried out on a medium containing erythromycin 
(3 µg/mL). Several EmR clones were cultured at 37оС 
for a night, seeded into plates containing the LB me-
dium with erythromycin (3 µg/mL) and incubated for 
24 h at 37оС. EmR recombinants were formed by inte-
gration of the pNZT1-purN-purD plasmid into the cor-
responding chromosome locus, which was attested by 
PCR amplification of the fragment consisting of 2413 
bp using N1 and D2 primers. Several EmR clones were 
seeded into an antibiotic-free liquid LB medium and 
incubated on a shaker at 30оС for 48 h. This was fol-
lowed by seeding onto plates with an antibiotic-free 
LB medium and incubation for another 24 h at 30оС. 
The excision of the integrated pNZT1 plasmid from the 
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resulting clones was tested. This was detected by the 
emergence of erythromycin-sensitive clones. As noted 
above, plasmid excision can be accompanied by either 
the retention of the wild-type allele of the purH gene in 
the chromosome, or by substitution of this allele for the 
ΔpurH deletion (Fig. 3). The integration (transfer) of 
the ΔpurH deletion into the chromosome of the АМ764 
purR::neo ΔT-purE strain was attested by the produc-
tion of a PCR fragment (with a size of 2413 np) with the 
participation of N1 and D2 primers. One of the variants 
of the АМ764 purR::neo ΔT-purE strain comprising the 
ΔpurH deletion and called AM778 was capable of ac-
cumulating up to 4–5 g/L of AICAR in CL and grew on 
the minimal medium only upon addition of hypoxan-
tine, adenine, or guanine, suchwise the presence of the 
defect purH gene in its genome was confirmed. Simul-
taneously, the control strain АМ793 was constructed: 
it contained ΔpurH, but it carried no purR::neo and 
ΔT-purE mutations, which provide derepression of the 
enzymes that involved in purine biosynthesis.
It was reasonable to increase the intracellular content 
of PRPP, the key precursor of purine biosynthesis; in 
order to enhance the productivity of the strain obtained 
(Fig. 1). It is well known that PRPP synthases that are 
responsible for PRPP synthesis in the cell of both B. sub-
tilis [35] and E. coli [36] are susceptible to allosteric in-
hibition by purine nucleotides, including phosphoryl-
ated derivatives of AICAR. As previously mentioned in 
the introduction section, the mutant variant of PRPP 
synthase of E. coli, which is not susceptible to allosteric 
regulation, has been described [22]. Therefore, the goal 
was to obtain an analogous mutant enzyme of E. coli, to 
clone it, and to optimize the expression of this enzyme 
in strain AM778 cells. However, prior to this, the inte-
grative expression vector had to be constructed, which 
could provide a high level of expression of heterologous 
E. coli genes in B. subtilis cells.
Construction of the integrative expression vector 
based on pDG268 plasmid
The pDG268 plasmid was selected as starting mate-
rial in order to obtain the integrative expression vec-
tor. This plasmid can be replicated in E. coli (but not 
B. subtilis) cells. However, when introduced into B. sub-
tilis cells, it may  integrate into the chromosome locus 
amyE of B. subtilis. The pDG268 plasmid comprises a 
cartridge that includes the polylinker, lacZ reporter 
gene without the intrinsic promoter, and the chloram-
phenicol (CmR) resistance gene (Fig. 4). The cartridge is 
flanked by fragments of the amyE gene, which permits 
integration of the vector with the cloned fragment into 
the amyE locus on the B. subtilis chromosome.
The promoter of the rpsF gene encoding the ribo-
somal protein S6 in bacilla was selected as a promoter 
that is capable of providing a high level of expression 
of the cloned E. coli genes in B. subtilis cells. The pro-
moters of ribosomal protein genes have been known to 
belong to the strongest promoters in B. subtilis; their 
expression is coordinated with the bacterial growth 
rate and attains a maximum level at the logarithmic 
growth stage [37, 38]. The nucleotide sequence of the 
rpsF gene promoter is shown in Fig. 5. As follows from 
Fig. 5, the PrpsF promoter contains the canonic sequence 
-70...-50 np, the so-called UP element, which provides a 
more efficient transcription initiation [39].
With the purpose of cloning the PrpsF promoter into 
the pDG268 plasmid, the DNA fragment containing 
the promoter region of the rpsF gene was amplified by 
PCR from the B. subtilis 168 chromosome using R1 and 
R2 primers (Table 2). The resulting PCR fragment was 
digested with the restriction endonucleases EcoRl and 
BamHI and cloned into the pDG268 plasmid digested 
with the same restrictases (Fig. 4). The E. coli TG1 
strain was transformed by a ligase mixture. The trans-
formants carrying the insertion of the desired fragment 
were sampled from an indicator medium containing 
ampicillin at a concentration of 120 µg/mL and X-gal. 
Transformant colonies were bright blue, since it was 
revealed that the lacZ reporter gene was controlled by 
Fig. 4. A schematic representation of cloning procedure 
of E. coli prs and purF genes under the control of the 
B. subtilis rpsF gene promoter in the plasmid pDG268, 
and their integration into the B. subtilis chromosome.
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the cloned PrpsF promoter. The presence of the insertion 
was confirmed by PCR using R1 and R2 primers. The 
resulting plasmid was then integrated into the chromo-
some amyE locus of B. subtilis by selecting the chlo-
ramphenicol (CmR)-resistent transformants. The sche-
matic representation of the integration of the pDG268 
vector with the cloned B. subtilis rpsF gene promoter is 
provided in Fig. 4. The determination of the activity of 
β-galactosidase in these transformants revealed that 
the lacZ reporter gene expression under control of the 
PrpsF promoter was higher than the expression of this 
gene when controlled by common promoters, such as 
the natural pur-operon promoter (no data presented), 
by an order of magnitude. The vector constructed was 
named pLE1.
Site-directed mutagenesis of the prs E. coli (prsE) gene
According to the published data, specific mutation in 
the prsE gene, resulting in the Asp128 → Ala replace-
ment in PRPP synthase, leads to the removal of ret-
roinhibition  of the enzyme by purine nucleotides [22]. 
In order to achieve the analogous mutation, synthesis 
of the oligonucleotide primers P3 and P4 (Table 2) was 
performed; the primers contain nucleotide replace-
ments (are denoted by uppercase letters) resulting in 
the formation of a mutant protein with the Asp128 → 
Ala replacement. At the first stage, PCR fragments 
were amplified with the participation of two primer 
pairs: P4–P1 (it flanks the 5’-terminus of the  prsE 
gene and contains the recognition site for restrictase 
ClaI). Then, the obtained fragments were joined, and 
the full-size prsE gene was amplified using the P1 and 
P2 primers (Table 2). It should be emphasized that the 
nucleotide sequence of the ribosome recognition site 
(SD) optimized for expression in bacilli is included into 
the 5’-region of the P1 primer. At the next stage, the 
P1-P2 PCR fragment containing the mutant prsE gene 
was cloned into the earlier obtained pLE1 vector using 
BamHI and ClaI restrictases. As a result, pLE2 plasmid 
containing the mutant prsE gene controlled by the PrpsF 
promoter was obtained. At the final stage, pLE2 plas-
mid was integrated into the amyE B. subtilis chromo-
some locus according to the earlier described scheme 
(Fig. 4). The strain obtained by integration of the pLE2 
plasmid was named AM811 (Table 1).
Site-directed mutagenesis of the purF E. coli (purFE) 
gene
The first enzyme of purine biosynthesis, glutamine-
PRPP aminotransferase (purF gene), plays the primary 
role in ensuring the normal functioning of the purine 
biosynthetic path in E. coli and B. subtilis. In addition, it 
is susceptible to allosteric regulation with the participa-
tion of nucleotides, which is even more sophisticated in 
comparison with the PRPP synthase [40]. Therefore, it 
could be expected that the use of the mutant glutamin-
PRPP aminotransferase from E. coli that is analogous 
to that described in [25] will lead to AICAR production. 
According to [25], Lys326 → Gln and Pro410 → Trp re-
placements in the protein modify the GMP (A-site) and 
AMP binding site (C-site), respectively.  Combination of 
these mutations leads to the enzyme being resistant to 
almost any purine nucleotide. Site-directed mutagen-
esis of the purFE gene was performed according to the 
scheme described in the previous section. The F3 and 
F4 oligonucleotide primers were synthesized to obtain 
the Lys326 → Gln replacement; and F4 and F5 primers, 
to obtain the Lys326 → Gln replacement (in Table 2, the 
corresponding nucleotide replacements are highlighted 
by uppercase letters and set off in bold). After the PCR 
amplification of these primers with the flanking prim-
ers F1 and F2, followed by the joining of the PCR frag-
ments, the full-size purFE gene encoding the protein 
with both amino acid replacements was obtained. As 
found in the case of the prsE gene, the SD site optimized 
for bacilli was introduced into primer F1. The modified 
purFE gene was cloned into the pLE1 plasmid under the 
control of the PrpsF promoter at the ClaI and EspI sites. 
The modified purFE gene was cloned into the pLE2 
plasmid containing the prsE gene using the same pro-
cedure. The corresponding plasmids were named pLE3 
and pLE4 (Table 1). At the final stage, plasmids pLE3 
and pLE4 were integrated into the amyE B. subtilis 
chromosome locus according to the scheme described 
above (Fig. 4). The strains obtained by integrating plas-
mids pLE3 and pLE4 were named АМ813 and АМ815, 
respectively (Table 1).
Determination of the ability of strains to accumulate 
AICAR
The fermentation experiments were carried out under 
the conditions described in the experimental section, in 
order to estimate the ability of the strains obtained in 
this study to accumulate AICAR. The results of these 
experiments are summarized in Fig. 6.
As follows from the data given in Fig. 6, the initial 
АМ732 strain accumulates almost no AICAR. Only af-
ter the purH gene has been removed from the genome 
of this strain (AM793 strain) is a negligible (< 1 g/L) ac-
cumulation of AICAR in CL observed. The mutations of 
purR::neo and ΔT-purE (AM788 strain) ensuring com-
plete derepression of the enzymes of purine biosynthe-
sis result in a considerable accumulation of AICAR; up 
to 4–5 g/L. A subsequent, almost two-fold enhance-
ment of productivity was observed for the AM811 and 
AM813 strains expressing one of the mutant desensi-
bilized E. coli proteins — PRPP synthase (prs gene) or 
glutamine-PRPP aminotransferase (purF gene). The RESEARCH ARTICLES
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maximum accumulation of AICAR (up to 11–13 g/L) 
was detected for the AM815 strain, which is character-
ized by the complete derepression of enzymes of purine 
biosynthesis and simultaneously contains the modified 
prsE and purFE genes controlled by the PrpsF promoter.
It is of interest that almost all of the AICAR synthe-
sized in cells is excreted in CL: it was demonstrated in 
special experiments that the intracellular concentra-
tion of AICAR is no higher than 2% of its concentration 
within the medium. The mechanism of AICAR excre-
tion remains unknown, although data was obtained 
indicating that the membrane protein encoded by the 
pbuE gene is involved in its export from bacilli cells [41].
The different stages in constructing the AICAR pro-
ducer are directed towards the stimulation of purine 
nucleotide biosynthesis; therefore, the AICAR that is 
detected in CL is formed upon dephosphorylation of 
the AICAR-P nucleotide synthesized de novo, as op-
posed to being the secondary product of histidine bio-
synthesis. Since AICAR-P is the natural analogue of 
AMP, while AICAR is the analogue of adenosine, the 
increased content of these compounds in producer 
cells is apparently accompanied by multiple metabolic 
events (see above); their impact as regards AICAR pro-
duction is far from clear. In a microorganism, AICAR-P 
cells serve not only as an intermediate of purine me-
tabolism, but also as a regulatory molecule of all-cell 
significance. The transformation of AICAR-P into IMP 
requires the participation of N10-formyltetrahydro-
folate; therefore, the increase in the level of AICAR-P 
in cells may be a warning of monocarbon metabolism 
disorder, which earlier has made it possible to regard 
this nucleotide as an alarmone [42]. Regardless of the 
fact that prokaryotes do not have a target for AICAR-
P that would be similar to animal AMPK, the direction-
ality of the physiological action of this AMP analogue is 
retained in them. In particular, inactivation of the purH 
gene in Salmonella enterica and AICAR-P accumula-
tion in cells result in the suppression of the activity of 
fructose-1,6-bisphosphate phosphatase. As a result, 
the cells lose their ability for gluconeogenesis and stop 
growing on glycerol and other gluconeogenic substrates 
[43]. In cells of prokaryotes and lower eukaryotes (e.g., 
yeast), a certain amount of AICAR-P is formed as a 
side product of histidine biosynthesis, which allows 
additional opportunities for the regulation of purine 
nucleotide biosynthesis [44]. The numerous regulatory 
bonds of AICAR-P that remain incompletely studied 
complicate the construction of producing strains and 
require further investigation.
CONCLUSIONS
The strain-producer of AICAR, a new drug with po-
tentially wide therapeutic applications, was obtained 
in studies based on B. subtilis bacteria. The strategy 
obtaining the AICAR producing strain is based on the 
directed reconstruction of purine metabolism in B. sub-
Fig. 5. Nucleotide sequence of 
the rpsF gene promoter. -10 
and -35 regions shown in 
bold uppercase. Positions +1 
defined as transcription start of 
pur-operon. The UP-element 
of the promoter is boxed. The 
nucleotide sequence of the 
primers used for cloning of the 
promoter are marked in blue. 
Fig 6. Construction stages of AICAR-producing strains 
and their productivity.
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tilis cells. At the first stage of the study, an insertion 
was introduced into the purR gene encoding the pur-
operon repressor protein, and the transcription at-
tenuator was removed from the leader region of the 
pur-operon, ensuring maximum derepression of the 
enzymes of de novo purine biosynthesis. The purH gene 
encoding formyltransferase/IMP-cyclohydrolase was 
then removed from the bacterial genome. Inactivation 
of this enzyme disturbs the reaction of AICAR conver-
sion into IMP and results in its accumulation in the cell. 
At the next stage, the site-directed mutagenesis of prs 
and purF E. coli genes encoding the key enzymes of the 
synthesis of purine precursors was carried out in order 
to obtain mutant variants of these genes that would not 
be susceptible to retroinhibition by purine nucleotides. 
Finally, at the last stage, the modified prs and purF E. 
coli genes were integrated into the B. subtilis chromo-
some under the control of a strong promoter ensuring 
a high level of expression of these genes in B. subtilis 
cells. As a result, we obtained a producing strain accu-
mulating 11–13 g/L of AICAR in CL.
To summarize, we would like to note that it was re-
ported recently that AICAR had successfully passed 
the stage IIa of clinical trials as a antitumor agent [45]. 
AICAR has a positive effect upon chronic lymphocytic 
leukemia, multiple myeloma, and mantle cell lympho-
ma. It should be emphasized that the cost of commercial 
AICAR substances in catalogues varies from US$100 to 
1,000 per gram, which is likely due to the fact that they 
are prepared by chemical synthesizing. The high cost 
makes AICAR inaccessible for research and a fortiori for 
treatment of the metabolic syndrome. The AICAR-pro-
ducing strain constructed by us may lay the foundations 
for industrial microbiological production of an affordable 
AICAR substance that would cost substantially less. 
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